NCT01966445View on ClinicalTrials.gov

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

November 26, 2013

Primary Completion Date

September 18, 2017

Study Completion Date

September 18, 2017

Conditions
CancerNeoplasms
Interventions
BIOLOGICAL

GSK2849330

Solution containing 100 mg/millilter (mL) GSK2849330 for intravenous infusion

Trial Locations (14)

3004

GSK Investigational Site, Melbourne

3084

GSK Investigational Site, Heidelberg

6009

GSK Investigational Site, Nedlands

10065

GSK Investigational Site, New York

80045

GSK Investigational Site, Aurora

84112

GSK Investigational Site, Salt Lake City

1066 CX

GSK Investigational Site, Amsterdam

1066 C

GSK Investigational Site, Amsterdam

9713 GZ

GSK Investigational Site, Groningen

9713 G

GSK Investigational Site, Groningen

6525 GA

GSK Investigational Site, Nijmegen

6525 G

GSK Investigational Site, Nijmegen

3075 EA

GSK Investigational Site, Rotterdam

3075 E

GSK Investigational Site, Rotterdam

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY